Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Treating Neonatal Opioid Withdrawal

The rise in opioid use in the United States has an unpleasant residual effect; an increase in pregnant women suffering from an opioid use disorder. Subsequently, there is a need to treat an increasing number of infants with neonatal opioid withdrawal syndrome (NOWS). This condition can lead to devastating effects for the infant, including severe…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

The rise in opioid use in the United States has an unpleasant residual effect; an increase in pregnant women suffering from an opioid use disorder. Subsequently, there is a need to treat an increasing number of infants with neonatal opioid withdrawal syndrome (NOWS). This condition can lead to devastating effects for the infant, including severe withdrawal symptoms and development issues.

How is healthcare meeting this challenge? Luckily, clinicians, researchers, and healthcare companies are working on solutions.

On this episode of Vital Spark, a Spark Biomedical podcast, Dan Wagner, Chief Commercial Officer of Spark Biomedical, spoke with two people from the Medical University of South Carolina. They are actively involved in treating this disorder. Dorothea Jenkins, M.D., Professor of Pediatrics, Medical University of South Carolina Division of Neonatology, and Bashar Badran, Ph.D., Assistant Professor in the College of Medicine Department of Psychiatry and the Behavioral Sciences Medical University of South Carolina, spoke about their combined efforts utilizing translational therapies with neurostimulation on babies with NOWS.

Jenkins and Badran discuss:

The effects of certain opioids on the neurology of the brains of babies

New non-evasive brain stimulation treatments to combat NOWS

Learnings from utilizing auricular neurostimulation on babies with NOWS

“We are on track towards the better understanding of reasonable, high-ranking hypothesis that may be the reason why we get such beneficial effects of auricular neurostimulation,” Badran said.”

Dorothea Jenkins, M.D. is a professor of Pediatrics at the Medical University of South Carolina Division of Neonatology who does research and translational therapies for babies with brain injuries. She collaborates with Dr. Bashar Badran on treating babies with neurostimulation with brain injury who are trying to learn motor skills.

Bashard Badran, Ph.D., is an assistant professor in the College of Medicine Department of Psychiatry and Behavioral Sciences at the Medical University of South Carolina. He is a neuroscientist who works on brain stimulation research and device development.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

FDA clears UpDoc's LLM diabetes app, grants Aidoc breakthrough status as clinical AI crosses new regulatory thresholds

FDA clears UpDoc's LLM diabetes app, grants Aidoc breakthrough status as clinical AI crosses new regulatory thresholds

UpDoc has received FDA clearance for its LLM-driven diabetes management app, while Aidoc has been granted breakthrough device status for its AI-drafted radiology reports. This marks a significant milestone as clinical AI applications continue to gain regulatory approval and recognition. The advancements showcase the potential of AI in improving healthcare management and diagnostic processes.

  • 01UpDoc's diabetes management app receives FDA clearance.
  • 02Aidoc achieves breakthrough device status for AI radiology reports.
  • 03Regulatory milestones highlight AI's growing role in healthcare.

Jul 13, 2026

Cedars-Sinai's CDAIO on healthcare AI's second wave: workforce transformation, not just productivity

Cedars-Sinai's CDAIO on healthcare AI's second wave: workforce transformation, not just productivity

The chief data and AI officer at Cedars-Sinai discusses the evolving role of AI in healthcare. While the first wave of AI focused on enhancing productivity, the second wave is expected to transform job roles and the workforce structure. This shift indicates a deeper integration of AI technology in healthcare operations.

  • 01First wave of AI increased productivity in healthcare.
  • 02Second wave aims to restructure job roles.
  • 03AI will deeply integrate into healthcare operations.

Jul 13, 2026

Automation adoption gap widens in US manufacturing as medtech presses ahead

Automation adoption gap widens in US manufacturing as medtech presses ahead

Automation in US manufacturing lags, with 80% of factories lacking automation tools. In contrast, medtech manufacturers are advancing with technologies like micro-molding and ultrasonic welding. This disparity highlights a growing gap in technology adoption across different sectors.

  • 0180% of US factories have no automation.
  • 02Medtech manufacturers are investing in automation technologies.
  • 03There's an increasing divide in technology adoption across industries.

Jul 12, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512